Article

1 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



@@#116300@@

Journal of the American Academy of Dermatology
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le jeudi 26 septembre 2019
Doi : 10.1016/j.jaad.2019.04.067
accepted : 26 April 2019
The human papillomavirus vaccine as a treatment for human papillomavirus–related dysplastic and neoplastic conditions: A literature review
 

Christine T. Pham, BS a, b, , Margit Juhasz, MD b, Calvin T. Sung, MD c, Natasha Atanaskova Mesinkovska, MD b
a University of California, Irvine School of Medicine, Irvine, California 
b Department of Dermatology, University of California, Irvine, California 
c University of California, Riverside, California 

Correspondence to: Christine T. Pham, BS, University of California, Irvine, Department of Dermatology, 843 Health Sciences Rd, Irvine, CA.University of California, IrvineDepartment of Dermatology843 Health Sciences RdIrvineCA
Abstract
Background

Human papillomavirus (HPV) infections are associated with common dermatologic and nondermatologic diseases. Although HPV vaccines are well established as preventive measures for genital warts and cervical neoplasia, their use as therapeutic agents deserves greater attention.

Objective

To evaluate the use of HPV vaccine(s) as a treatment modality for cutaneous and/or mucosal disease.

Methods

A primary literature search using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines was conducted in January 2019 by using the PubMed and Cochrane databases.

Results

A total of 63 articles with 4439 patients were included. The majority of patients with cutaneous warts, recurrent respiratory papillomatosis, and squamous and basal cell carcinomas were successfully treated with HPV vaccination. Preliminary data on patients with pre-existing anogenital warts, cervical intraepithelial neoplasia, anal intraepithelial neoplasia, and vulvar intraepithelial neoplasia is promising.

Limitations

This review was limited by the lack of controls, patients' previous HPV vaccination status, and publication bias.

Conclusion

The commercially available three-dose, quadrivalent HPV vaccine is a potential therapeutic option for the treatment of cutaneous warts, recurrent respiratory papillomatosis, and squamous and basal cell carcinomas. Noncommercially available HPV vaccines demonstrate therapeutic response for treating anogenital warts, cervical intraepithelial neoplasia, anal intraepithelial neoplasia, and vulvar intraepithelial neoplasia. The vaccine's efficacy as an adjunct therapy for HPV-associated cutaneous and/or mucosal disease warrants further exploration.

The full text of this article is available in PDF format.

Key words : human papillomavirus, neoplasia, nonmelanoma skin cancer, vaccine, viral warts

Abbreviations used : AIN, BCC, CIN, HPV, RRP, SCC, VAIN, VIN



 Funding sources: None.
 Conflicts of interest: None disclosed.
 Reprints not available from the authors.



© 2019  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline